Abstract Biallelic mutations in the SBF1 gene have been identified in one family with demyelinating Charcot-MarieTooth disease (CMT4B3) and two families with axonal neuropathy and additional neurological and skeletal features. Here we describe novel sequence variants in SBF1 (c.1168C>G and c.2209_2210del) as the potential causative mutations in two siblings with severe axonal neuropathy, hearing loss, facial weakness and bulbar features. Pathogenicity of these variants is supported by co-segregation and in silico analyses and evolutionary conservation. Our findings suggest that SBF1 mutations may cause a syndromic form of autosomal recessive axonal neuropathy (AR-CMT2) in addition to CMT4B3.
Introduction
Charcot-Marie-Tooth disease (CMT), a genetically heterogeneous disorder of the peripheral nerves, is classically divided into demyelinating or axonal subtypes based on neurophysiology data. Mutations in genes encoding myotubularin-related proteins (MTMR2 and SBF2) are associated with autosomal recessive forms of demyelinating CMT (CMT4B1 and CMT4B2, respectively) [1, 2] . Mutations in the SBF1 gene, which encodes another member of the myotubularin family, have been identified in one Korean family with autosomal recessive demyelinating CMT (CMT4B3) but also in one Saudi Arabian and one Syrian family with axonal neuropathy, multiple cranial neuropathies, intellectual disability and skeletal features including microcephaly [3] [4] [5] [6] [7] . In this paper, we describe novel variants in SBF1 as the potential causative mutations in two siblings with severe axonal neuropathy, hearing loss, facial weakness and bulbar features. Our findings support the previous observation that SBF1 mutations may cause a syndromic form of axonal neuropathy in addition to CMT4B3.
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Methods
Two brothers with peripheral neuropathy were investigated. Informed consent was obtained from all individuals and the institutional review boards at the participating medical centres approved the study. Individuals underwent clinical and instrumental assessments during the routine diagnostic process. Neurophysiological studies, MRI scans and skin, muscle and nerve biopsies were performed using standard methods. Genomic DNA from the two affected individuals and four unaffected relatives was used for molecular genetic analyses. For detailed methods see the online supplementary material.
Results
Clinical features The proband and his affected brother (II:3 and II:2; Fig. 1a) were the third and second children of healthy, non-consanguineous parents of Spanish descent. Both walked independently at age 14 months. At ages 4 and 9 years, respectively, they were noted to have an unsteady gait and subsequently developed slowly progressive, distal-predominant, muscle weakness and sensory loss in their limbs. They lost ambulation in their mid to late 30s. In their late 40s, on neurological examination, they had gaze-evoked nystagmus (plus delayed initiation of horizontal saccades and mild ophthalmoparesis in patient II:3), bilateral hearing loss, upper and lower facial weakness, bulbar features including tongue weakness, dysarthria, dysphagia and reduced or absent gag reflex, lumbar hyperlordosis, mild pes cavus, distal and proximal muscle weakness and atrophy and marked sensory impairment in their limbs (Table 1 and Fig. 1c-d ). They were unable to stand unaided. Their IQ was 85 and 83, respectively.
Nerve conduction studies were consistent with a severe length-dependent motor and sensory axonal neuropathy with median and ulnar motor nerve conduction velocities ranging between 49 and 61 m/s (supplementary Table1). Compound muscle action potentials of the facial nerves were markedly reduced in patient II:3. Needle EMG showed neurogenic motor unit action potentials in the limbs and facial muscles (supplementary Table 2 ). In patient II:3, brainstem auditory evoked potentials were consistent with left sensorineural cochlear impairment and visual evoked potentials showed no abnormalities.
Creatine kinase levels were 290 IU/L in patient II:3 and 420 IU/L in patient II:2 (normal values ≤195 IU/L). Brain MRIs in both cases demonstrated mild cerebellar atrophy ( Fig. 1e-f ). Skin, tibialis anterior muscle and sural nerve biopsies were performed in patient II:3 at age 34 years. Skin biopsy was unremarkable. Muscle biopsy showed features of longstanding neurogenic atrophy. Nerve biopsy revealed diffuse loss of myelinated axons of all diameters, few regenerating clusters and occasional moderately thin myelin sheaths; no onion bulbs were observed. The final histopathological diagnosis was axonal neuropathy (Fig. 1g-h ). Muscle biopsy of patient II:2 at age 32 years also showed features of longstanding neurogenic atrophy.
Genetic results Genetic analysis of the 17p11.2 chromosome region and direct sequencing of GJB1, AAAS, SLC52A2 and SLC52A3 genes revealed no pathogenic variants. Genetic tests for spinal muscular atrophy, Kennedy's disease, Friedreich ataxia, spinocerebellar ataxia types 1, 2, 3, 6, 7, 8, 12 and 17, dentatorubral-pallidoluysian atrophy, and fragile Xassociated tremor/ataxia syndrome were also negative. To identify the underlying genetic cause, we applied wholeexome sequencing on the proband (II:3) and one unaffected brother (II:1). Analysis focused on nonsynonymous, splicesite and coding indel variants with a minor allele frequency (MAF) of <0.5% in the Exome Aggregation Consortium (ExAC; exac.broadinstitute.org), Exome Variant Server (EVS; evs.gs.washington.edu) and 1000 Genomes databases (1000G; www.1000genomes.org). From a total of 613 variants that met these filtering criteria in the proband, 186 variants in 60 genes co-segregated under an autosomal recessive model and 2 variants in 2 genes under a X-linked model. Of these 188 variants, only 3 involved a gene associated with inherited neuropathy, i.e. the SBF1 gene (supplementary Table 3 ). No potentially pathogenic sequence variants were detected in known genes associated with cerebellar ataxia or hearing loss.
The SBF1 variants were validated by Sanger sequencing (supplementary Fig.) . Segregation analysis confirmed that both affected siblings and their unaffected father were heterozygotes for the SBF1 variants c.2209_2210del and c.5197C>T, indicating that these two variants were located in the same allele, and that all affected and unaffected siblings and their mother were heterozygous for the SBF1 variant c.1168C>G (Fig. 1a) . c.2209_2210del and c.1168C>G are novel variants not previously reported in public databases (supplementary Table 4 ). c.1168C>G, located in exon 11 of t h e S B F 1 g e n e ( 4 1 e x o n s ; E n s e m b l t r a n s c r i p t ENST00000380817), leads to the substitution of positively charged arginine for neutral glycine at codon 390 (p. Arg390Gly), affects a highly conserved nucleotide (Fig. 1b) and amino acid and is predicted as being deleterious by pathogenicity prediction tools. c.2209_2210del, located in exon 19, creates a frame shift starting at codon 737 that ends in a premature stop codon 2 positions downstream (p. Leu737Glufs*3).
c.5197C>T is reported in the dbSNP database (rs199972466) and is present in 62 individuals, including one homozygote, in the ExAC database (MAF = 0.053%; supplementary Table 4 ). This variant is located in exon 38 and leads to the substitution of positively charged arginine for neutral cysteine at codon 1733 (p. Arg1733Cys). c.5197C>T is predicted as being deleterious; however, in the two affected individuals from the present study, this variant was in cis with c.2209_2210del, which causes a premature stop codon 994 amino acids upstream. Thus, the contribution of c.5197C>T to the observed phenotype is uncertain.
Discussion
Using whole-exome sequencing in two siblings with a severe motor and sensory axonal neuropathy, hearing loss, facial weakness and bulbar features, we have identified two novel Myotubularins comprise a group of catalytically active and inactive proteins involved in membrane trafficking and endocytosis [8, 9] . Inactive myotubularins such as SBF1 and SBF2 interact with and regulate their active homologues by heterodimerization, and coiled-coil domains seem to be crucial for this interaction [8] [9] [10] . SBF1 interacts with the MTMR2 lipid phosphatase and deletion of the coiled-coil domain of SBF1 leads to an altered cellular localization of MTMR2 in vitro [10] . The frameshift mutation p. Leu737Glufs*3 detected in our family may result in a truncated SBF1 protein lacking the coiled-coil domain, which could affect the activity and distribution of MTMR2. Alternatively, the mutation may cause lack of expression due to nonsensemediated decay. Of note, nonsense and frameshift mutations are common in SBF2-related CMT4B2 [2, 11, 12] . Both SBF1 and SBF2 but not MTMR2 contain DENN domains involved in regulation of Rab GTPases, which are in turn central regulators of membrane trafficking [13] . Mutations affecting the dDENN motif of the DENN domain or nearby amino acid residues have been identified in two families with CMT4B (p. Met417Val in SBF1 and p. Leu351_Glu432del in SBF2) and syndromic forms of axonal neuropathy (p. Leu335Pro and p. Asp443Asn in SBF1) [3] [4] [5] [6] [7] 14] . The novel variant p. Arg390Gly detected in our family is also located within the dDENN motif of SBF1, which suggests functional relevance.
Our cases have several similarities with the previously reported Saudi Arabian and Syrian families carrying the homozygous SBF1 variants p. Asp443Asn and p. Leu335Pro, respectively (clinical features summarized in supplementary Table 5 ) [4] [5] [6] [7] . Ophthalmoparesis, facial weakness, dysarthria and dysphagia were present in all families with variable frequency and severity, and neurophysiological exam was consistent with an axonal neuropathy in all individuals although sensory and motor nerve conduction velocities were mildly decreased in one case. Some of the features observed in the previously reported families, however, including strabismus, microcephaly and moderate-to-severe intellectual disability, were absent in our cases. We believe that these three families share a new syndromic form of autosomal recessive axonal neuropathy (AR-CMT2) with multiple cranial neuropathies. Nevertheless, given the phenotypic variability and the previous association of SBF1 mutations with CMT4B3, additional studies are needed to further define the clinical spectrum of SBF1-related neuropathies.
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